Other clinical trials use therapeutic antibodies against DLL4 to inhibit Notch signaling (presumably targeting Notch expressed on the CSC) in combination with paclitaxel in ovarian, peritoneal, and fallopian tube cancer (NCT03030287); in combination with FOLFIRI (irinotecan, folic acid, leucovorin, and fluorouracil), in metastatic colorectal cancer (NCT01189942); or the anti-DLL4 antibody demcizumab in combination with Gemcitabine Abraxane on metastatic pancreatic cancer (NCT01189929). The gene discussed is DLL4; the disease is metastatic colorectal cancer.